The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
Globe Newswire (Wed, 18-Mar 11:30 AM ET)
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Globe Newswire (Tue, 17-Mar 4:05 PM ET)
Longeveron's March 2026 Financial Results Date Signals Renewed Focus on Pipeline Progress
Market Chameleon (Fri, 13-Mar 6:30 AM ET)
Longeveron Secures $15 Million Upfront in Private Placement, Extending Cash Runway Into Late 2026
Market Chameleon (Thu, 12-Mar 7:46 AM ET)
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Globe Newswire (Thu, 12-Mar 9:00 AM ET)
Longeveron Announces Closing of Private Placement of up to $30 Million
Globe Newswire (Wed, 11-Mar 4:05 PM ET)
Longeveron’s $30M Private Placement Extends Cash Runway Beyond Key Clinical Milestone
Market Chameleon (Tue, 10-Mar 5:54 AM ET)
Longeveron Announces Private Placement of up to $30 Million
Globe Newswire (Tue, 10-Mar 9:00 AM ET)
Globe Newswire (Wed, 25-Feb 11:05 AM ET)
Longeveron Appoints Stephen H. Willard as Chief Executive Officer
Globe Newswire (Fri, 13-Feb 4:30 PM ET)
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Longeveron - Class A trades on the NASDAQ stock market under the symbol LGVN.
As of April 2, 2026, LGVN stock price declined to $1.07 with 1,114,591 million shares trading.
LGVN has a beta of 0.63, meaning it tends to be less sensitive to market movements. LGVN has a correlation of 0.01 to the broad based SPY ETF.
LGVN has a market cap of $31.33 million. This is considered a Sub-Micro Cap stock.
Last quarter Longeveron - Class A reported $365,000 in Revenue and -$.22 earnings per share. This beat revenue expectation by $258,802 and exceeded earnings estimates by $.16.
In the last 3 years, LGVN traded as high as $44.00 and as low as $.48.
The top ETF exchange traded funds that LGVN belongs to (by Net Assets): VTI, VXF.
LGVN has underperformed the market in the last year with a price return of -31.4% while the SPY ETF gained +17.5%. However, in the short term, LGVN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +80.4% vs -3.7% return in SPY. But in the last 2 weeks, LGVN shares have been beat by the market, returning -3.6% compared to an SPY return of -0.1%.
LGVN support price is $1.01 and resistance is $1.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGVN shares will trade within this expected range on the day.
